📊 AVTX Key Takeaways
Is Avalo Therapeutics, Inc. (AVTX) a Good Investment?
Avalo Therapeutics is a pre-revenue pharmaceutical company with severe cash burn and deteriorating financial condition. The company has depleted its revenue to zero with a 77.1% YoY decline, burning $37.2M in operating cash flow annually against only $27.0M in cash reserves, indicating a critical liquidity runway of less than 9 months. With persistent operating losses of $53.2M, negative returns on equity and assets exceeding -50%, and substantial long-term debt, the company faces imminent financing pressure or potential insolvency.
Avalo Therapeutics shows the classic profile of a highly speculative, pre-revenue biotech with no operating revenue, deeply negative operating and net income, and materially negative free cash flow. While the balance sheet is not heavily levered and near-term liquidity ratios look strong, the absolute cash balance appears limited relative to ongoing cash burn, making future dilution or financing risk a central fundamental concern.
Why Buy Avalo Therapeutics, Inc. Stock? AVTX Key Strengths
- Strong current ratio of 14.28x suggests adequate short-term liquidity relative to current liabilities
- Moderate debt-to-equity ratio of 0.16x indicates conservative leverage relative to equity base
- Positive insider activity with 9 Form 4 filings in last 90 days may suggest management confidence
- Low balance-sheet leverage with debt/equity of 0.16x limits financial strain versus heavily indebted peers
- High current and quick ratios indicate minimal near-term liability pressure
- Positive YoY EPS improvement suggests some loss-per-share compression, likely helped by capital structure changes or cost control
AVTX Stock Risks: Avalo Therapeutics, Inc. Investment Risks
- Critical cash runway of approximately 8 months at current burn rate with only $27.0M cash against $37.2M annual operating cash burn
- Complete revenue collapse to $0 (77.1% YoY decline) indicating failed commercialization or pipeline setbacks
- Persistent operating losses of $53.2M and net losses of $64.5M with negative ROE of -70.5% and ROA of -51.6% demonstrating severe unprofitability
- High interest coverage ratio of -83.8x indicates inability to service debt from operations
- Unsustainable business model requiring immediate capital raise or strategic alternatives to avoid dilution or bankruptcy
- Zero revenue and sharply declining top line indicate no commercial base to support operations
- Large operating and free cash flow losses point to weak profitability quality and ongoing cash consumption
- Cash of $26.96M appears thin relative to negative operating cash flow of $37.21M, raising funding and dilution risk
Key Metrics to Watch
- Monthly cash burn rate and updated cash runway forecast
- Clinical trial progress updates and pipeline advancement milestones
- Any fundraising announcements or debt restructuring activities
- Operating cash flow trajectory and quarterly cash position
- Quarterly operating cash burn versus cash and equivalents
- Clinical/regulatory progress that can translate into sustainable revenue generation
Avalo Therapeutics, Inc. (AVTX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.28x current ratio provides a solid financial cushion.
AVTX Profit Margin, ROE & Profitability Analysis
AVTX vs Healthcare Sector: How Avalo Therapeutics, Inc. Compares
How Avalo Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Avalo Therapeutics, Inc. Stock Overvalued? AVTX Valuation Analysis 2026
Based on fundamental analysis, Avalo Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Avalo Therapeutics, Inc. Balance Sheet: AVTX Debt, Cash & Liquidity
AVTX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Avalo Therapeutics, Inc.'s revenue has declined by 93% over the 5-year period, indicating business contraction. The most recent EPS of $-20.91 indicates the company is currently unprofitable.
AVTX Revenue Growth, EPS Growth & YoY Performance
AVTX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | $210.0K | $-2.19 |
| Q3 2024 | $236.0K | $210.0K | $-2.83 |
| Q2 2024 | N/A | -$8.2M | $-14.07 |
| Q1 2024 | N/A | -$10.0M | $-141.00 |
| Q3 2023 | $236.0K | $3.2M | $-0.11 |
| Q2 2023 | $643.0K | -$8.2M | $-0.59 |
| Q1 2023 | $475.0K | -$10.0M | $-0.85 |
| Q3 2022 | $1.4M | $3.2M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Avalo Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
AVTX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Avalo Therapeutics, Inc. (CIK: 0001534120)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 10, 2026 | DEF 14A | avtx-20260408.htm | View → |
| Apr 8, 2026 | 4 | xslF345X06/form4-04082026_080437.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_070439.xml | View → |
| Apr 3, 2026 | 4 | xslF345X06/form4-04032026_070418.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/form4-04012026_040410.xml | View → |
❓ Frequently Asked Questions about AVTX
What is the AI rating for AVTX?
Avalo Therapeutics, Inc. (AVTX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AVTX's key strengths?
Claude: Strong current ratio of 14.28x suggests adequate short-term liquidity relative to current liabilities. Moderate debt-to-equity ratio of 0.16x indicates conservative leverage relative to equity base. ChatGPT: Low balance-sheet leverage with debt/equity of 0.16x limits financial strain versus heavily indebted peers. High current and quick ratios indicate minimal near-term liability pressure.
What are the risks of investing in AVTX?
Claude: Critical cash runway of approximately 8 months at current burn rate with only $27.0M cash against $37.2M annual operating cash burn. Complete revenue collapse to $0 (77.1% YoY decline) indicating failed commercialization or pipeline setbacks. ChatGPT: Zero revenue and sharply declining top line indicate no commercial base to support operations. Large operating and free cash flow losses point to weak profitability quality and ongoing cash consumption.
What is AVTX's revenue and growth?
Avalo Therapeutics, Inc. reported revenue of $0.0.
Does AVTX pay dividends?
Avalo Therapeutics, Inc. does not currently pay dividends.
Where can I find AVTX SEC filings?
Official SEC filings for Avalo Therapeutics, Inc. (CIK: 0001534120) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AVTX's EPS?
Avalo Therapeutics, Inc. has a diluted EPS of $-5.47.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AVTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Avalo Therapeutics, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AVTX stock overvalued or undervalued?
Valuation metrics for AVTX: ROE of -70.5% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AVTX stock in 2026?
Our dual AI analysis gives Avalo Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AVTX's free cash flow?
Avalo Therapeutics, Inc.'s operating cash flow is $-37.2M, with capital expenditures of $95.0K.
How does AVTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -70.5% (avg: 15%), current ratio 14.28 (avg: 2).